Advances in therapy: Eribulin improves survival for metastatic breast cancer

Anti-Cancer Drugs

Volumn 21, Issue 10, 2010, Pages 885-889

  Morris, Patrick G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Eisai Metastatic Breast Cancer Study Assessing Physician's Choice versus Eribulin study; Eribulin; Halichondrin B; Metastatic breast cancer; Microtubule agen

Indexed keywords

ANTHRACYCLINE; BETA TUBULIN; BEVACIZUMAB; CAPECITABINE; EPOTHILONE DERIVATIVE; ERIBULIN; GEMCITABINE; IXABEPILONE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; VINCA ALKALOID;

ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GENE MUTATION; HAZARD RATIO; HUMAN; HYPOGLYCEMIA; HYPOPHOSPHATEMIA; MAXIMUM TOLERATED DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; ETHERS, CYCLIC; FEMALE; FURANS; HUMANS; INFUSIONS, INTRAVENOUS; KETONES; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 78650054235     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833ed62e     Document Type: Review

References (38)

1. Stewart BW, Kleihues P. World Cancer Report. In: Stewart BW, Kleihues P, editors. World Cancer Report. Lyon: IARC Press; 2003.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-1717.
4. Morris PG, McArthur HL, Hudis CA. Therapeutic options for metastatic breast cancer. Expert Opin Pharmacother 2009; 10:967-981.
5. Murphy CG, Fornier M. HER2-positive breast cancer: beyond trastuzumab. Oncology (Williston Park) 2010; 24:410-415.
6. Morris PG, Hudis CA. Personalizing therapy for metastatic breast cancer. Expert Rev Anticancer Ther 2009; 9:1223-1226.
7. O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial (Abstract 3). Proc Am Soc Clin Oncol 2009; 27:18s.
8. Uemura D, Takahashi K, Yamamoto T, Katayama C, Tanaka J, Okumura Y, et al. Norhalichondrin A: an antitumor polyether macrolide from a marine sponge. J Am Chem Soc 1985; 107:4796-4798.
9. Hirata Y, Uemura D. Halichondrins: antitumor polyether macrolides from a marine sponge. Pure Appl Chem 1986; 58:701-710.
10. Jimeno A. Eribulin: rediscovering tubulin as an anticancer target. Clin Cancer Res 2009; 15:3903-3905.
11. Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 2008; 14:7167-7172.
12. Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 1991; 266:15882-15889.
13. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005; 4:1086-1095.
14. Aicher TD, Buszek KR, Fang FG, Forsyth CJ, Jung SH, Kishi Y, et al. Total synthesis of halichondrin B and norhalichondrin B. J Am Chem Soc 1992; 114:3162-3164.
15. Morris PG, Fornier MN. Novel anti-tubulin cytotoxic agents for breast cancer. Expert Rev Anticancer Ther 2009; 9:175-185.
16. Kuznetsov G, TenDyke K, Yu MJ, Littlefield B. Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro (Abstract C58). Proc Am Assoc Cancer Res 2007; 2007:C58.
17. Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004; 64:5760-5766.
18. Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001; 61:1013-1021.
19. Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 2010; 49:1331-1337.
20. Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 2008; 7:2003-2011.
21. Tan AR, Rubin EH, Walton DC, Shuster DE, Wong YN, Fang F, et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009; 15:4213-4219.
22. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26:1642-1649.
23. Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS,Wong N, et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009; 15:4207-4212.
24. Synold T, Morgan R, Newman E, Lenz H, Gandara D, Colevas A, et al. A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer Consortium trial. Proc Am Soc Clin Oncol 2005; 16S: Abstract 3036.
25. Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009; 27:2954-2961.
26. Cortes J, Vahdat L, Twelves C, Allison M, Campone M, Shuster D, et al. Phase II study of eribulin mesylate (E7389) in patients with locally advanced or metastatic breast cancer previously treated with anthracycline, taxane, and capecitabine therapy. J Clin Oncol 2010. [Epub ahead of print]
27. Twelves C, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet PJ, et al. A phase III study (EMBRACE) of eribulin mesylate vs. treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. Proc Am Soc Clin Oncol 2010; 28:18s. (suppl; abstr CRA1004).
28. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28:3239-3247.
29. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-2676.
30. Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) (Abstract 1005). Proc Am Soc Clin Oncol 2009; 27:15s. (suppl; abstr 1005).
31. Twelves C, Cortes J, Vahdat LT,Wanders J, Akerele C, Kaufman PA. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer 2010; 10:160-163.
32. E7389 vs. Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes. http:// clinicaltrials.gov/show/NCT00337103 [Accessed 6 November 2010].
33. Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer. http:// clinicaltrials.gov/show/NCT00879086 [Accessed 6 November 2010].
34. Synold TW, Tsao-Wei DD, Quinn DI, Groshen SG, Aparicio A, Twardowski P, et al. Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): a California Cancer Consortium Trial (Abstract 2527). Proc Am Soc Clin Oncol 2010; 28:15s. (suppl; abstr 2527).
35. Witteveen P, Marchetti S, Mergui-Roelvink M, Reyderman L, Copalu W, Wanders J, et al. Eribulin mesylate pharmacokinetics in patients with hepatic impairment (Abstract 2582). Proc Am Soc Clin Oncol 2010; 28:15s. (suppl; abstr 2582).
36. Quinn DI, Aparicio A, Tsao-Wei DD, Groshen SG, Dorff TB, Synold TW, et al. Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)-Final report: a California Cancer Consortium-led NCI/CTEP-sponsored trial. Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)-Final report: a California Cancer Consortium-led NCI/CTEP-sponsored trial (Abstract 4539). Proc Am Soc Clin Oncol 2010; 28:15s. (suppl; abstr 4539).
37. Stein MN, Chen Y, Hudes GR, Carducci MA, Tan W, DiPaola RS. ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) (Abstract 4556). Proc Am Soc Clin Oncol 2010; 28:15s. (suppl; abstr 4556).
38. Schoffski P, Ray-Coquard IL, Cioffi A, Bin Bui N, Bauer S, Hartmann JT, et al. Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052) (Abstract 10031). Proc Am Soc Clin Oncol 2010; 28:15s. (suppl; abstr 10031).